- Conditions
- Atherosclerosis
- Interventions
- darapladib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 625–648
of 6,517
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neurofibromatosis 1, Neurofibroma, Plexiform
- Interventions
- Medication Event Monitoring System (MEMS^TM), Questionnaires
- Behavioral · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 59 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF), Low T3 Syndrome
- Interventions
- Liothyronine, Placebo
- Drug · Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Uveitis
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified, Central Nervous System Ganglioneuroblastoma, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered, Pineoblastoma, Primary Central Nervous System Neoplasm, Recurrent Childhood Central Nervous System Embryonal Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Rhabdomyosarcoma
- Interventions
- Adavosertib, Irinotecan Hydrochloride
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
- Conditions
- Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
- Interventions
- CP-547,632
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Santa Monica, California • Baltimore, Maryland + 2 more
- Conditions
- Cholera
- Interventions
- PXVX0200, placebo
- Biological
- Lead sponsor
- Bavarian Nordic
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 197 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Cincinnati, Ohio • Burlington, Vermont
- Conditions
- Hepatitis C, Chronic Pain
- Interventions
- Alisporivir, Peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 16
- States / cities
- La Jolla, California • San Diego, California • Ventura, California + 9 more
- Conditions
- Lymphomas, Tumors
- Interventions
- Irinotecan
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Nonhematologic Malignancies, Lymphoma
- Interventions
- Ixazomib 2.5 mg, Ixazomib 4 mg Capsule A, Ixazomib 4 mg Capsule B, Ketoconazole, Rifampin, Clarithromycin
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Patients Requiring Abdominopelvic CT With Oral Administration of Contrast
- Interventions
- Iopamidol
- Drug
- Lead sponsor
- Bracco Diagnostics, Inc
- Industry
- Eligibility
- Not listed
- Enrollment
- 218 participants
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Akron, Ohio
- Conditions
- Soft Tissue Sarcoma
- Interventions
- ridaforolimus
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Obstetric Labour, Premature, Premature Ejaculation
- Interventions
- GSK557296
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Evansville, Indiana
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Gastrointestinal Stromal Tumors, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Central Nervous System Tumor, Central Nervous System Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control
- Interventions
- Not listed
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 110 Years
- Enrollment
- 999,999 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2099
- U.S. locations
- 42
- States / cities
- Greenwood Village, Colorado • Manchester, Connecticut • Daytona Beach, Florida + 34 more
- Conditions
- Healthy
- Interventions
- PF-06865571, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Schizophrenia
- Interventions
- SKL15508, Placebo
- Drug
- Lead sponsor
- SK Life Science, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Multiple Sclerosis
- Interventions
- Fampridine-SR, Placebo
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
- Conditions
- Healthy Participants
- Interventions
- [14C]-tebapivat, [13C2,15N3]-tebapivat
- Drug
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Vomiting, Nausea, Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- Casopitant (GW679769) oral tablets, Casopitant (GW679769) intravenous, Dexamethasone intravenous, Ondansetron oral tablets, placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Fayetteville, Arkansas + 78 more
- Conditions
- Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
- Interventions
- BGJ398 (infigratinib)
- Drug
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 5 more
- Conditions
- Dentin Sensitivity
- Interventions
- Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0), Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5), Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )
- Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 221 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Fort Wayne, Indiana
- Conditions
- Contraception
- Interventions
- Norethindrone acetate/ethinyl estradiol
- Drug
- Lead sponsor
- Warner Chilcott
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 1,683 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 66
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 52 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Cetuximab, BIBW 2992
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • New Haven, Connecticut • New York, New York + 1 more
- Conditions
- Healthy Volunteers
- Interventions
- Ortho-Cyclen, Evacetrapib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Dallas, Texas